Drug Eluting Stent News and Research

RSS
A drug-eluting stent (DES) is a coronary stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.
CRF initiates Harmonizing Outcomes with Revascularization and Stents in AMI II trial

CRF initiates Harmonizing Outcomes with Revascularization and Stents in AMI II trial

Medtronic Resolute DES found effective through two years

Medtronic Resolute DES found effective through two years

Symposium to cover latest breakthroughs in percutaneous treatment of CAD

Symposium to cover latest breakthroughs in percutaneous treatment of CAD

FDA approves Boston Scientific's ION and TAXUS Liberte paclitaxel-eluting stents

FDA approves Boston Scientific's ION and TAXUS Liberte paclitaxel-eluting stents

FDA approves Medtronic's Resolute Integrity DES to treat CAD

FDA approves Medtronic's Resolute Integrity DES to treat CAD

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

U.S. District Court rules in favor of Boston Scientific in PROMUS patent infringement case

U.S. District Court rules in favor of Boston Scientific in PROMUS patent infringement case

Reva Medical commences its first clincial trial

Reva Medical commences its first clincial trial

Drug-coated balloon restores blood flow in narrowed bare metal stent

Drug-coated balloon restores blood flow in narrowed bare metal stent

Elixir Medical announces initiation of DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System study

Elixir Medical announces initiation of DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System study

Svelte initiates Rapamycin-eluting stent with bio-Eroding Carrier Technology implantation study

Svelte initiates Rapamycin-eluting stent with bio-Eroding Carrier Technology implantation study

Micell announces preliminary data from MiStent Sirolimus DES clinical study

Micell announces preliminary data from MiStent Sirolimus DES clinical study

DSM and Svelte Medical Systems enter into license and supply agreement

DSM and Svelte Medical Systems enter into license and supply agreement

Medtronic highlights scientific sessions of interest on program for TCT 2011

Medtronic highlights scientific sessions of interest on program for TCT 2011

FDA approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

FDA approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

FDA's Circulatory System Devices Panel unanimously recommends Cook Medical's Zilver PTX Drug-Eluting Stent

FDA's Circulatory System Devices Panel unanimously recommends Cook Medical's Zilver PTX Drug-Eluting Stent

HCRI completes enrollment in dual antiplatelet therapy clinical trial

HCRI completes enrollment in dual antiplatelet therapy clinical trial

Xience V stent performs well in patients with primary PCI for ST elevation myocardial infarction

Xience V stent performs well in patients with primary PCI for ST elevation myocardial infarction

Everolimus-eluting stent and SES are equally effective for PCI patients

Everolimus-eluting stent and SES are equally effective for PCI patients

Abbott initiates ABSORB BVS device clinical trial in coronary artery disease

Abbott initiates ABSORB BVS device clinical trial in coronary artery disease